Kaur Sumanpreet, Bhattacharyya Rajasri, Banerjee Dibyajyoti
Department of Experimental Medicine and Biotechnology, Postgraduate Institute of Medical Education and Research, Chandigarh, 160012 India.
In Silico Pharmacol. 2020 Nov 12;8(1):5. doi: 10.1007/s40203-020-00056-9. eCollection 2020.
Hypertension is a public health concern. Low dose thiazide diuretics are known to effectively control blood pressure compared to that of other classes of antihypertensive drugs. In this context, we have performed an in-silico study and found that the two Sulphonamide Diuretics Hydrochlorothiazide and Indapamide bound the NADPH binding region of bacterial Dihydrofolate Reductase. Therefore, akin to Sulphonamide Antibiotics, Sulphonamide Diuretics may have antibiotic activity and thereby have the potential to modulate the gut microbiome in a way beneficial to vascular health. The in-silico experiment results were analyzed in the context of the relevant literature. We postulate that Sulphonamide Diuretics exert their antihypertensive role by modulating the gut microbiome, specifically by increasing butyrate-producing taxa in the gut. We recommend extending such work as it is plausible that Indapamide and other Sulphonamide Diuretics may be beneficial for both diabetes and hypertension.
高血压是一个公共卫生问题。与其他类别的抗高血压药物相比,低剂量噻嗪类利尿剂已知能有效控制血压。在此背景下,我们进行了一项计算机模拟研究,发现两种磺胺类利尿剂氢氯噻嗪和吲达帕胺与细菌二氢叶酸还原酶的NADPH结合区域结合。因此,与磺胺类抗生素类似,磺胺类利尿剂可能具有抗生素活性,从而有可能以有利于血管健康的方式调节肠道微生物群。在相关文献的背景下分析了计算机模拟实验结果。我们推测磺胺类利尿剂通过调节肠道微生物群发挥其降压作用,特别是通过增加肠道中产生丁酸盐的分类群。我们建议扩展此类研究,因为吲达帕胺和其他磺胺类利尿剂可能对糖尿病和高血压都有益,这是有道理的。